Metabolic bone diseases : what's new in 2023].

The sequential effects of romosozumab and denosumab in osteoporosis are shown in real-life, while the mechanisms of post-denosumab rebound are reviewed extensively. A network meta-analysis confirms the superiority of anabolics vs anti-resorptives on fracture reduction, while the latter shown a reduction of mortality in a large population-based study. Fracture risk prediction by FRAXPlus is improved. New meta-analyses confirm the benefits of Vitamin D on fractures and falls. Finally, multiples trials with new molecules for the treatment of rare bone diseases, including osteogenesis imperfecta, fibrous dysplasia and hypoparathyroidism, shown promising results.

Citation

Serge Ferrari, Andrea Trombetti, Anne-Cecile Debrach, Sarah Kozycki, Ivan Padlina, Thierry Chevalley, Emmanuel Biver. Metabolic bone diseases : what's new in 2023]. Revue medicale suisse. 2024 Jan 31;20(859):255-258

Mesh Tags

Substances

PMID: 38299957

search → result